Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients

NCT01983293 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to analyze the effect of left ventricular lead pacing location in the non-left bundle branch block (non-LBBB) heart failure patient population. The left ventricular lead pacing location will be guided by either the pacing site with the largest amount of dyssynchrony as measured by the LV electrical delay (QLV) or the physician's standard of care implant approach.

Interventions

  • DEVICE QLV based implant strategy
  • DEVICE Standard of care implant strategy

Study Locations (20)

California

  • Glendale Adventist Medical Center — Glendale
  • USC University Hospital — Los Angeles
  • Mission Hospital — Mission Viejo
  • St. Joseph's Medical Center — Stockton

Georgia

  • Piedmont Heart Institute — Atlanta
  • Emory University Hospital — Atlanta
  • Atlanta Heart Associates - Riverdale — Riverdale

Michigan

  • Henry Ford Hospital — Detroit
  • St. John Hospital and Medical Center — Detroit
  • McLaren Macomb — Mount Clemens

Florida

  • Baker-Gilmour Cardiovascular Institute — Jacksonville
  • Northside Hospital — St. Petersburg

Kentucky

  • Central Baptist Hospital — Lexington
  • University of Kentucky — Lexington

Massachusetts

  • Tufts Medical Center — Boston
  • Massachusetts General Hospital — Boston

Louisiana

  • Oschner Medical Center — New Orleans

Maryland

  • Johns Hopkins University Hospital — Baltimore

Trial Details

FieldValue
Enrollment Target 248 participants
Start Date 2013-11
Est. Completion 2018-01
Phase NA

Sponsor

Abbott Medical Devices

155 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01983293

The ClinicalTrials.gov registry entry for NCT01983293 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Non-left Bundle Branch Block appearing as the primary indexed condition, and to 2 interventions — of which QLV based implant strategy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01983293 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, Georgia, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01983293 about?

NCT01983293 is a clinical study titled "CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients". The purpose of this study is to analyze the effect of left ventricular lead pacing location in the non-left bundle branch block (non-LBBB) heart failure patient population. The left ventricular lead pacing location will be guided by either the pacing site with the largest amount of dyssynchrony as m...

What is the current status of trial NCT01983293?

This trial is currently completed. It is a NA study. The enrollment target is 248 participants. The study started on 2013-11. Estimated completion is 2018-01.

What conditions does trial NCT01983293 study?

This clinical trial studies the following conditions: Non-left Bundle Branch Block, Ischemic or Non-ischemic Cardiomyopathy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01983293?

The interventions under investigation include: QLV based implant strategy (DEVICE), Standard of care implant strategy (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01983293?

This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01983293 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial